Senokot 7.5mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Senna fruit

Available from:

Reckitt Benckiser Healthcare (UK) Ltd

ATC code:

A06AB06

INN (International Name):

Senna fruit

Dosage:

7.5mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 01060200; GTIN: 5000158062832 5000158062818 5000158066830 5000158065215

Patient Information leaflet

CUSTOMER INFO:
Minimum Point Size =
9.00pt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
BARCODE INFO
Barcode Type:
Barcode Number:
Magnification:
Truncated By:
Full Height:
Bar Height (Smallest Bar):
BWR:
Encoded Data:
Trident Reference No:
ZEN Ref:
Action:
Brand:
Category:
Segment Group:
Segment:
Pack Size:
Market/Country:
Date:
Component Code
(2D if applicable)
:
2
nd
Component Code
(if applicable)
:
Parent Technical Packaging Specification:
Finished Goods Code:
Supply Point:
3rd Party Code
Pharmacode No/NE:
Edgemark Position:
CAD Cam Ref:
Printer:
Substrate:
N/A
N/A
RB Hull
N/A
0000000
Senokot
Stimulant Laxative
Senna
Regular Tablet
20Pack
RB482518
Please note that any low resolution paper Canon colour copies
associated with this job should be referred to for content, layout
and colour separation only.
STUDIO USE ONLY
v2.0
Sm•Art check results:
Cutter
Guides
Technical & Non Printing Items
Cutter 2 (if applicable)
Guides 2 (if applicable)
Multi Packaging Solutions (Tewkesbury, UK)
Skt-Lft-D8372157-160mmx250mm
TR2244001
Paper White
UK
21/07/21
A
Senthamil Tamilmani
0000000
N/A
G=2; O=0; R=0; - ST - 21/07/21 15:46:14
RB Artwork and
Print Specification
D8372157
Artwork Type:
BW Submission
10
mm
20
30
40
50
60
70
80
90
100
110
120
130
140
150
160
170
180
190
200
210
220
230
240
250
1
LTH
PANTONE 347 C
Colours (Leaflet)
RBH Contact:
Alexander Titmus
Connaught House, Connaught Road,
Kingswood Business Park, Hull, HU7 3AP, England.
T: [phone]
UNDER NO CIRCUMSTANCES SHOULD THIS
ARTWORK BE ALTERED WITHOUT PRIOR
PERMISSION FROM TRIDENT.
0000000
0000000
PACKAGE LEAFLET: INFORMATION FOR THE USER
SENOKOT 7.5 MG TABLETS ADULT
SENNA FRUIT (PODS)
READ THIS LEAFLET CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION
FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
Ask your pharmacist if you need more information or advice.
•
Always take this medicine exactly as described in this leaflet or as
your doctor or pharmacist have
told you.
•
If any of the side effects get serious or if you notice any side
effec

Summary of Product characteristics

1
NAME OF THE MEDICINAL PRODUCT
Senokot 7.5 mg Tablets Adult
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains powdered Alexandrian Senna fruit (pods) (_Cassia
senna _L._ _(_C. acutifolia _
Delile)) and Tinnevelly Senna fruit (pods) (_Cassia angustifolia
_Vahl) equivalent to 7.5mg
hydroxyanthracene glycosides, calculated as sennoside B.
Each tablet also contains 15.82 mg lactose monohydrate
For full list of excipients, see section 6.1
3
PHARMACEUTICAL FORM
Tablets
4.1
THERAPEUTIC INDICATIONS
For the short-term relief of occasional constipation.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
For oral administration.
The correct individual dose is the smallest required to produce a
comfortable soft-
formed motion.
Adults and the elderly: Swallow one to two tablets at night
Should not be used in children or adolescents under the age of 18
years.
New users should start with the lowest dose and increase it to the
maximum dose if
necessary. Once regularity has been regained dosage should be reduced
and can
usually be stopped.
If no bowel action has occurred after three days of progressively
increased dosage, a
medical examination should be considered.
Duration of use
Not to be used for more than 1 week. Usually it is sufficient to take
this medicinal product up
to two to three times during that week.
If the symptoms persist during the use of the medicinal product, a
doctor or a pharmacist
should be consulted.
See also section 4.4 Special warnings and precautions for use.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients.
Not to be used at the same time as other laxative agents.
Cases of intestinal obstructions and stenosis, atony, appendicitis,
inflammatory bowel
diseases (e.g Crohn’s disease, ulcerative colitis), abdominal pain
of unknown origin,
severe dehydration state with water and electrolyte depletion
4.4
SPECIAL WARNINGS AND PRECAUTIONS FOR USE
If the symptoms worsen during the use of the medicinal product or
there is no bowel
movement after three days, a doct